• 1
    Ferrari S, Smeland S, Mercuri M et al . Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 2005; 23: 884552.
  • 2
    Lewis VO. What's new in musculoskeletal oncology. J Bone Joint Surg Am 2007; 89: 1399407.
  • 3
    Campbell CJ, Cohen J, Enneking WF. Editorial: New therapies for osteogenic sarcoma. J Bone Joint Surg Am 1975; 57: 1434.
  • 4
    Kawaguchi S, Wada T, Tsukahara T et al . A quest for therapeutic antigens in bone and soft tissue sarcoma. J Transl Med 2005; 3: 31.
  • 5
    Meyers PA, Schwartz CL, Krailo M et al . Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 2005; 23: 200411.
  • 6
    Maki RG. Future directions for immunotherapeutic intervention against sarcomas. Curr Opin Oncol 2006; 18: 3638.
  • 7
    Mocellin S, Mandruzzato S, Bronte V, Lise M, Nitti D, Part I. Vaccines for solid tumours. Lancet Oncol 2004; 5: 6819.
  • 8
    Van Baren N, Bonnet MC, Dreno B et al . Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol 2005; 35: 900821.
  • 9
    Thurner B, Haendle I, Roder C et al . Vaccination with MAGE-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999; 190: 166978.
  • 10
    Morgan RA, Dudley ME, Wunderlich JR et al . Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314: 1269.
  • 11
    Nabeta Y, Kawaguchi S, Sahara H et al . Recognition by cellular and humoral autologous immunity in a human osteosarcoma cell line. J Orthop Sci 2003; 8: 5549.
  • 12
    Tsukahara T, Nabeta Y, Kawaguchi S et al . Identification of human autologous cytotoxic T-lymphocyte-defined osteosarcoma gene that encodes a transcriptional regulator, papillomavirus binding factor. Cancer Res 2004; 64: 54428.
  • 13
    Boeckle S, Pfister H, Steger G. A new cellular factor recognizes E2 binding sites of papillomaviruses which mediate transcriptional repression by E2. Virology 2002; 293: 10317.
  • 14
    Sichtig N, Silling S, Steger G. Papillomavirus binding factor (PBF)-mediated inhibition of cell growth is regulated by 14–3–3 beta. Arch Biochem Biophys 2007; 464: 909.
  • 15
    Tsukahara T, Kawaguchi S, Ida K et al . HLA-restricted specific tumor cytolysis by autologous T-lymphocytes infiltrating metastatic bone malignant fibrous histiocytoma of lymph node. J Orthop Res 2006; 24: 94101.
  • 16
    Al-Batran SE, Rafiyan MR, Atmaca A et al . Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma. Cancer Res 2005; 65: 393741.
  • 17
    Tsukahara T, Kawaguchi S, Torigoe T et al . Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5. Cancer Sci 2006; 97: 137480.
  • 18
    Enneking WF. A system of staging musculoskeletal neoplasms. Clin Orthop Relat Res 1986; 204: 924.
  • 19
    Rosen G, Nirenberg A. Neoadjuvant chemotherapy for osteogenic sarcoma: a five year follow-up (T-10) and preliminary report of new studies (T-12). Prog Clin Biol Res 1985; 201: 3951.
  • 20
    Wada T, Isu K, Takeda N, Usui M, Ishii S, Yamawaki S. A preliminary report of neoadjuvant chemotherapy NSH-7 study in osteosarcoma: preoperative salvage chemotherapy based on clinical tumor response and the use of granulocyte colony-stimulating factor. Oncology 1996; 53: 2217.
  • 21
    Yonemoto T, Tatezaki S, Ishii T, Satoh T, Kimura H, Iwai N. Prognosis of osteosarcoma with pulmonary metastases at initial presentation is not dismal. Clin Orthop Relat Res 1998; 349: 1949.
  • 22
    Ishii T, Tatezaki S. The results of a cooperative study of chemotherapy for osteosarcoma (NECO 93J). J Jpn Orthop Assoc 1999; 73: S1129.
  • 23
    Isu K, Yamawaki S, Beppu Y et al . Prognostic results from multi-institute study of adjuvant chemotherapy for osteogenic sarcoma. J Jpn Orthop Assoc 1999; 73: S1135.
  • 24
    Kaya M, Wada T, Nagoya S, Kawaguchi S, Isu K, Yamashita T. Concomitant tumour resistance in patients with osteosarcoma. A clue to a new therapeutic strategy. J Bone Joint Surg Br 2004; 86: 1437.
  • 25
    The JOA Musculo-Skeletal Tumor Comittee. General Rules for Clinical and Pathological Studies on Malignant Bone Tumors, 2nd edn. Tokyo: Kanabara, 2000.
  • 26
    Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994; 152: 16375.
  • 27
    Kuzushima K, Hayashi N, Kimura H, Tsurumi T. Efficient identification of HLA-A*2402-restricted cytomegalovirus-specific CD8 (+) T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay. Blood 2001; 98: 187281.
  • 28
    Ida K, Kawaguchi S, Sato Y et al . Crisscross CTL induction by SYT-SSX junction peptide and its HLA-A*2402 anchor substitute. J Immunol 2004; 173: 143643.
  • 29
    Karanikas V, Lurquin C, Colau D et al . Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus. J Immunol 2003; 171: 4898904.
  • 30
    Sato Y, Nabeta Y, Tsukahara T et al . Detection and induction of CTLs specific for SYT-SSX-derived peptides in HLA-A24(+) patients with synovial sarcoma. J Immunol 2002; 169: 16118.
  • 31
    Dagher R, Long LM, Read EJ et al . Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study. Med Pediatr Oncol 2002; 38: 15864.
  • 32
    Kawaguchi S, Wada T, Ida K et al . Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma. J Transl Med 2005; 3: 1.
  • 33
    Yabe H, Tsukahara T, Kawaguchi S et al . Overexpression of papillomavirus binding factor in Ewing's sarcoma family of tumors coferring poor prognosis. Oncol Rep 2007; 19: 12934.
  • 34
    Lurquin C, Lethe B, De Plaen E et al . Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med 2005; 201: 24957.
  • 35
    Coulie PG, Karanikas V, Colau D et al . A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci USA 2001; 98: 102905.
  • 36
    So T, Hanagiri T, Chapiro J et al . Lack of tumor recognition by cytolytic T lymphocyte clones recognizing peptide 195–203 encoded by gene MAGE-A3 and presented by HLA-A24 molecules. Cancer Immunol Immunother 2007; 56: 25969.
  • 37
    Coulie PG, Connerotte T. Human tumor-specific T lymphocytes: does function matter more than number? Curr Opin Immunol 2005; 17: 3205.
  • 38
    Boon T, Coulie PG, Van den Eynde BJ, Van Der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol 2006; 24: 175208.
  • 39
    Speiser DE, Lienard D, Rufer N et al . Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005; 115: 73946.
  • 40
    Romero P, Cerottini JC, Speiser DE. The human T cell response to melanoma antigens. Adv Immunol 2006; 92: 187224.